Eli Lilly and Company has confirmed it’s selling its 25,000-square-foot manufacturing site in Branchburg. The decision was ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of GLP-1/amylin agonist amycretin that achieved reductions of between 10.4% and 13.1% in ...

Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume growth from Zepbound and Mounjaro. <li /> Increased the midpoint of o ...

When Eli Lilly reports its financial results early Thursday, investors will be looking for the company to press its advantage ...

Shares of Eli Lilly & Co. (LLY) were tumbling in early trading Thursday, after the drug giant disclosed late-stage trial data for its weight-loss pill that fell well short of expectations. The data ...

The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year or so.

People taking the new wonder drug orforglipron lost an average of 12.4 per cent of their body weight after 72 weeks and ...

A mother-of-two left with saggy boobs and a 'turkey neck' after losing 3 stone on Mounjaro claims she now feels 'complete' ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...